Diadema Partners’s Roivant Sciences ROIV Stock Holding History

Diadema Partners’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.3M	Buy	335,800 +17,100	+5%	+$439K	1.58%	23
2025 Q4	$6.92M	Buy	318,700 +18,700	+6%	+$369K	1.19%	26
2025 Q3	$4.54M	Buy	+300,000	New	+$3.71M	1.16%	30

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Diadema Partners's ROIV Position: Q4 2025 in Review

Diadema Partners sold out of Roivant Sciences (ROIV) in Q4 2025, closing a stake of 120,000 shares — an estimated $2.37M sold.

Diadema Partners first reported a position in ROIV in Q3 2025 and held it in 1 quarter. The position peaked at $1.82M in Q3 2025. 396 funds tracked by Wall St. Rank hold ROIV as of Q4 2025.

Diadema Partners reported no remaining Roivant Sciences position as of Q4 2025 after selling out during the quarter.
Diadema Partners sold 120,000 Roivant Sciences shares in Q4 2025, an estimated $2.37M.
Diadema Partners first reported a position in Roivant Sciences in Q3 2025 and held it in 1 quarter.
Diadema Partners's Roivant Sciences position peaked at $1.82M in Q3 2025.
396 funds tracked by Wall St. Rank held Roivant Sciences as of Q4 2025.

Based on Diadema Partners's 13F filing for Q4 2025, filed 17 Feb 2026.